Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells 58,283 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the sale, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

David Sponsel also recently made the following trade(s):

• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Stock Performance

Shares of NASDAQ ATEC opened at $11.29 on Friday. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $17.34. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -8.82 and a beta of 1.41. The stock’s fifty day moving average price is $9.63 and its two-hundred day moving average price is $8.05.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Barclays lifted their target price on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 19th. Needham & Company LLC raised their price target on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a report on Monday. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a report on Tuesday. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.44.

Hedge Funds Weigh In On Alphatec

A number of hedge funds have recently bought and sold shares of ATEC. Ballentine Partners LLC acquired a new position in shares of Alphatec during the 4th quarter worth approximately $120,000. Courier Capital LLC boosted its stake in shares of Alphatec by 76.9% in the fourth quarter. Courier Capital LLC now owns 69,000 shares of the medical technology company’s stock valued at $633,000 after buying an additional 30,000 shares during the period. Franklin Resources Inc. grew its position in Alphatec by 299.3% during the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock worth $343,000 after buying an additional 48,308 shares in the last quarter. Barclays PLC increased its stake in Alphatec by 362.3% during the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock worth $948,000 after acquiring an additional 133,653 shares during the period. Finally, Invst LLC raised its holdings in Alphatec by 3.7% in the 3rd quarter. Invst LLC now owns 158,549 shares of the medical technology company’s stock valued at $882,000 after acquiring an additional 5,630 shares in the last quarter. 66.35% of the stock is owned by institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.